Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Inventory (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Inventory for 5 consecutive years, with $25.8 million as the latest value for Q4 2025.

  • Quarterly Inventory rose 37.42% to $25.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.8 million through Dec 2025, up 37.42% year-over-year, with the annual reading at $25.8 million for FY2025, 37.42% up from the prior year.
  • Inventory for Q4 2025 was $25.8 million at Rhythm Pharmaceuticals, up from $22.1 million in the prior quarter.
  • The five-year high for Inventory was $25.8 million in Q4 2025, with the low at $111000.0 in Q4 2021.
  • Average Inventory over 5 years is $12.2 million, with a median of $10.3 million recorded in 2023.
  • The sharpest move saw Inventory surged 2527.93% in 2022, then soared 37.42% in 2025.
  • Over 5 years, Inventory stood at $111000.0 in 2021, then soared by 2527.93% to $2.9 million in 2022, then surged by 195.65% to $8.6 million in 2023, then skyrocketed by 117.31% to $18.7 million in 2024, then surged by 37.42% to $25.8 million in 2025.
  • According to Business Quant data, Inventory over the past three periods came in at $25.8 million, $22.1 million, and $18.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.